HPC
REGN icon

HM Payson & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

HM Payson & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.5K Sell
105
-50
-32% -$34K ﹤0.01% 659
2026
Q1 		$120K Sell
155
-15
-9% -$11.5K ﹤0.01% 525
2025
Q4 		$131K Sell
170
-25
-13% -$17K ﹤0.01% 506
2025
Q3 		$110K Buy
195
+45
+30% +$25.4K ﹤0.01% 543
2025
Q2 		$78.8K Buy
150
+35
+30% +$19.5K ﹤0.01% 576
2025
Q1 		$72.9K Buy
115
+100
+667% +$68.8K ﹤0.01% 578
2024
Q4 		$10.7K Sell
15
-1
-6% -$839 ﹤0.01% 835
2024
Q3 		$16.8K Buy
16
+15
+1,500% +$16.7K ﹤0.01% 783
2024
Q2 		$1.05K Buy
+1
New +$969 ﹤0.01% 952
2024
Q1 		– Sell
-15
Closed -$13.2K – 999
2023
Q4 		$13.2K Hold
15
– – ﹤0.01% 790
2023
Q3 		$12.3K Hold
15
– – ﹤0.01% 796
2023
Q2 		$10.8K Hold
15
– – ﹤0.01% 795
2023
Q1 		$12.3K Buy
+15
New +$11.3K ﹤0.01% 775
2022
Q3 		– Sell
-1
Closed -$1K – 1064
2022
Q2 		$1K Buy
+1
New +$650 ﹤0.01% 1012
2019
Q4 		– Sell
-30
Closed -$8K – 962
2019
Q3 		$8K Sell
30
-70
-70% -$20.7K ﹤0.01% 840
2019
Q2 		$31K Buy
+100
New +$33.3K ﹤0.01% 674

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HM Payson & Co's REGN Position: Q2 2026 in Review

HM Payson & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, selling an estimated $34K and leaving 105 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

HM Payson & Co first reported a position in REGN in Q2 2019 and has held it in 16 quarters since. The position peaked at $131K in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • HM Payson & Co held 105 shares of Regeneron Pharmaceuticals worth $65.5K as of Q2 2026.
  • HM Payson & Co sold 50 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $34K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #659 holding.
  • HM Payson & Co first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 16 quarters since.
  • HM Payson & Co's Regeneron Pharmaceuticals position peaked at $131K in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.